The Technical Analyst
Inogen Inc [INGN]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Inogen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
4.63% $6.78
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 159.65 mill |
| EPS: | -4.42 |
| P/E: | -1.530 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 23.55 mill |
| Avg Daily Volume: | 0.537 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.530 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -1.530 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.341 (-80.22%) $-5.44 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.25 - 7.25 ( +/- 7.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Bourque Michael J. | Buy | 75 000 | Restricted Stock Unit |
| 2024-03-04 | Bourque Michael J. | Buy | 0 | |
| 2024-03-01 | Somer Jason | Buy | 21 996 | Restricted Stock Unit |
| 2024-03-01 | Somer Jason | Buy | 7 150 | Common Stock |
| 2024-03-01 | Somer Jason | Sell | 4 680 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 46.45 |
| Last 95 transactions |
| Buy: 593 723 | Sell: 215 465 |
Forecast:
16:00 - $6.78
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.78
Forecast 2: 16:00 - $6.78
Forecast 3: 16:00 - $6.78
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.78 (4.63% ) |
| Volume | 0.149 mill |
| Avg. Vol. | 0.537 mill |
| % of Avg. Vol | 27.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $7.55 | N/A | Active |
|---|
INGN
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Latest Press Releases
2024-04-10 08:30:00 - Press Release
Inogen To Report First Quarter 2024 Financial Results On May 7, 2024
Goleta, calif.--(business wire)--inogen to report first quarter 2024 financial results on may 7, 2024.
2024-03-25 08:30:00 - Press Release
Inogen To Present At 23rd Annual Needham Virtual Healthcare Conference
Goleta, calif.--(business wire)--inogen to present at 23rd annual needham virtual healthcare conference.
2024-03-07 16:00:00 - Press Release
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Goleta, calif.--(business wire)--inogen, inc. (nasdaq: ingn), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that, effective march 4, 2024, the compensation committee of inogen's board of directors approved awards of restricted stock units as material inducement to michael bourque entering into employment with the company to serve as its executive vice president, chief financial officer and treasurer. the equity awards were.
2024-01-30 16:00:00 - Press Release
Inogen To Report Fourth Quarter And Full Year 2023 Financial Results On February 27, 2024
Goleta, calif.--(business wire)--inogen to report fourth quarter and full year 2023 financial results on february 27, 2024.
2024-01-24 16:00:00 - Press Release
Inogen Names Michael Bourque As New Chief Financial Officer
Goleta, calif.--(business wire)--inogen names michael bourque as new chief financial officer.
Latest News
2024-03-28 12:31:18 - Zacks Investment Research
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
2024-02-28 10:26:04 - Zacks Investment Research
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
2024-02-27 20:31:10 - Zacks Investment Research
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2024-02-27 19:26:12 - Zacks Investment Research
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.57 per share a year ago.
2024-02-26 10:21:25 - Zacks Investment Research
Gear Up for Inogen (INGN) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Inogen (INGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
2024-02-23 10:00:24 - Zacks Investment Research
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
2024-02-01 08:05:18 - Zacks Investment Research
Inogen (INGN) Surges 12.3%: Is This an Indication of Further Gains?
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2024-01-30 16:00:00 - Business Wire
Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
GOLETA, Calif.--(BUSINESS WIRE)--Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024.
2024-01-08 08:16:30 - Zacks Investment Research
Inogen (INGN) Soars 15.4%: Is Further Upside Left in the Stock?
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
2024-01-02 10:31:12 - Zacks Investment Research
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.